Back to Search
Start Over
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
- Source :
- BMC Musculoskeletal Disorders, Vol. 18, No Art. 174 (2017), BMC Musculoskeletal Disorders, Vol 18, Iss 1, Pp 1-8 (2017), BMC Musculoskeletal Disorders, BMC Musculoskeletal Disorders, 18
- Publication Year :
- 2017
- Publisher :
- Springer Science and Business Media LLC, 2017.
-
Abstract
- Background Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the study conduct had a higher risk of fracture than those who remained enrolled, thereby underestimating the true fracture risk for the entire trial cohort. Thus, we explored the influence of early withdrawals on nonvertebral fracture incidence during the Extension study. Methods To understand the potential effect of depletion of susceptible subjects on fracture incidence, we first evaluated subject characteristics in patients who were enrolled in the Extension vs those who were not. We subsequently employed a Kaplan-Meier multiple imputation (KMMI) approach to consider subjects who discontinued as if they remained enrolled with a 0%, 20%, 50%, and 100% increase in fracture risk compared with participants remaining on study. Results Extension enrollees were generally similar to nonparticipants in median age (71.9 and 73.1 years, respectively), mean total hip bone mineral density T-score (–1.9 and –2.0, respectively), and probability of fracture risk by Fracture Risk Assessment Tool (FRAX®) at FREEDOM baseline (16.9% and 17.7% for major osteoporotic fracture and 6.7% and 7.4% for hip fracture, respectively). When we assumed a doubled fracture risk (100% increase) after discontinuation in KMMI analyses, nonvertebral fracture rate estimates were only marginally higher than the observed rates for both the crossover group (10.32% vs 9.16%, respectively) and the long-term group (7.63% vs 6.63%, respectively). Conclusion The observation of continued denosumab efficacy over 8 years of treatment was robust and does not seem to be explained by depletion of susceptible subjects. Trial registration ClincalTrials.gov registration number NCT00523341; registered August 30, 2007 Electronic supplementary material The online version of this article (doi:10.1186/s12891-017-1520-6) contains supplementary material, which is available to authorized users.
- Subjects :
- Male
0301 basic medicine
medicine.medical_specialty
Patient Dropouts
lcsh:Diseases of the musculoskeletal system
Sports medicine
Osteoporosis
030209 endocrinology & metabolism
03 medical and health sciences
0302 clinical medicine
Rheumatology
Internal medicine
Extension study
Epidemiology
medicine
Humans
Orthopedics and Sports Medicine
ddc:610
Aged
Aged, 80 and over
Selection bias
ddc:616
Hip fracture
Bone Density Conservation Agents
Hip Fractures
business.industry
Incidence (epidemiology)
Middle Aged
medicine.disease
FREEDOM
Discontinuation
Surgery
Treatment Outcome
030104 developmental biology
Denosumab
Cohort
Female
lcsh:RC925-935
business
Osteoporotic Fractures
Research Article
medicine.drug
Subjects
Details
- ISSN :
- 14712474
- Volume :
- 18
- Database :
- OpenAIRE
- Journal :
- BMC Musculoskeletal Disorders
- Accession number :
- edsair.doi.dedup.....fddd76b26fd53d37171bc6a4cbb8269f
- Full Text :
- https://doi.org/10.1186/s12891-017-1520-6